NCT06264180Phase 3Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Study sponsor: Replimune, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-09-30Estimated
Enrollment · participants400Estimated
Source updated2026-07-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: 1 Jan 2029. After: 30 Sep 2030.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview